Table 1 Patient demographics and disease characteristics at baseline (efficacy population)
Parameter | Total N = 2536 (100%) |
|---|---|
Gender, n (%) | |
Male | 1441 (56.8) |
Female | 1095 (43.2) |
Mean (SD) age, y (n = 2532) | 57.8 (12.2) |
Mean (SD) weight, kg (n = 2504) | 78.8 (15.3) |
Mean (SD) height, cm (n = 2477) | 170.4 (8.5) |
Mean (SD) BMI, kg/m2 (n = 2477) | 27.1 (4.8) |
Race, n (%) | |
White | 2349 (92.6) |
Asian | 73 (2.9) |
Black | 7 (0.3) |
Other | 6 (0.2) |
Missing | 101 (4.0) |
Frequency of common symptoms, n (%) | |
Sputum purulence increased | 2021 (79.7) |
Worsening dyspnea | 1998 (78.8) |
Sputum volume increased | 1707 (67.3) |
Upper respiratory tract infection (past 5 days) | 1266 (49.9) |
Anthonisen grade, n (%) | |
Type I | 1089 (42.9) |
Type II | 1019 (40.2) |
Type III | 412 (16.2) |
Missing | 16 (0.6) |
Smoking status, n (%) | |
Past or current | 1367 (53.9) |
Never | 1159 (45.7) |
Missing | 10 (0.4) |
Years with chronic bronchitis, n (%) | |
< 1 | 127 (5.0) |
1-5 | 863 (34.0) |
> 5-10 | 748 (29.5) |
> 10 | 796 (31.4) |
Missing | 2 (0.1) |
Exacerbations in past 12 months | |
None | 478 (18.8) |
Yes | 2048 (80.8) |
1 | 479 (18.9) |
2 | 745 (29.4) |
3 | 420 (16.6) |
4 | 198 (7.8) |
5 | 97 (3.8) |
≥ 6 | 109 (4.3) |
Missing | 10 (0.4) |
Hospitalization due to AECB in past 12 months | |
None | 1867 (73.6) |
Yes | 668 (26.3) |
1 | 442 (17.4) |
2 | 164 (6.5) |
3 | 35 (1.4) |
4 | 10 (0.4) |
≥ 5 | 17 (0.7) |
Missing | 1 (< 0.1) |
Corticosteroid intake in past 12 months | |
Yes | 964 (38.0) |
No | 1571 (61.9) |
Missing | 1 (< 0.1) |
Antibiotic treatment for last AECB | |
Yes | 1577 (62.2) |
No | 959 (37.8) |
Missing | 0 (0.0) |